Search Results - "Larry House"

Influence of N‐acetyltransferase 2 gene polymorphisms on the in vitro metabolism of the epidermal growth factor receptor inhibitor rociletinib by Ramirez, Jacqueline, House, Larry K., Ratain, Mark J.

“…Aims Rociletinib showed activity in T790M‐positive non‐small cell lung cancer patients. It undergoes amide hydrolysis to form M502, followed by N‐acetylation…”
Get full text

Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer by INNOCENTI, Federico, SCHILSKY, Richard L, KARRISON, Theodore, MAITLAND, Michael L, SALGIA, Ravi, RATAIN, Mark J, RAMIREZ, Jacqueline, JANISCH, Linda, UNDEVIA, Samir, HOUSE, Larry K, DAS, Soma, KEHUA WU, TURCICH, Michelle, MARSH, Robert

“…The risk of severe neutropenia from treatment with irinotecan is related in part to UGT1A1*28, a variant that reduces the elimination of SN-38, the active…”
Get full text

Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10 by Ramírez, Jacqueline, Mirkov, Snezana, House, Larry K, Ratain, Mark J

“…OTS167 is a potent maternal embryonic leucine zipper kinase inhibitor undergoing clinical testing as antineoplastic agent. We aimed to identify the…”
Get full text

Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib by Ramírez, Jacqueline, House, Larry K., Karrison, Theodore G., Janisch, Linda A., Turcich, Michelle, Salgia, Ravi, Ratain, Mark J., Sharma, Manish R.

“…This study investigated the time course and magnitude of the pharmacokinetic interaction between capecitabine and the cytochrome P450 (CYP) 2C9 substrate…”
Get full text

Comparison of the Drug-Drug Interactions Potential of Erlotinib and Gefitinib via Inhibition of UDP-Glucuronosyltransferases by YONG LIU, RAMIREZ, Jacqueline, HOUSE, Larry, RATAIN, Mark J

“…We aimed to investigate and compare the effects of erlotinib and gefitinib on UDP-glucuronosyltransferase (UGT) activities and to quantitatively evaluate their…”
Get full text

Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing by Reizine, Natalie M., Danahey, Keith, Truong, Tien M., George, David, House, Larry K., Karrison, Theodore G., Wijk, Xander M. R., Yeo, Kiang‐Teck J., Ratain, Mark J., O’Donnell, Peter H.

“…BACKGROUND In recent years, there has been increasing evidence supporting the role of germline pharmacogenomic factors predicting toxicity for anticancer…”
Get full text

Personalized targeted therapy for lung cancer by Wu, Kehua, House, Larry, Liu, Wanqing, Cho, William C S

“…Lung cancer has long been recognized as an extremely heterogeneous disease, since its development is unique in every patient in terms of clinical…”
Get full text

Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies by GANGADHAR, Tara C, COHEN, Ezra E. W, FLEMING, Gini F, RATAIN, Mark J, KEHUA WU, JANISCH, Linda, GEARY, David, KOCHERGINSKY, Masha, HOUSE, Larry K, RAMIREZ, Jackie, UNDEVIA, Samir D, MAITLAND, Michael L

“…Sirolimus is the prototypical mTOR inhibitor. Sorafenib and sunitinib are small molecule inhibitors of multiple kinases including VEGF receptor (VEGFR)…”
Get full text

The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients by Ramírez, Jacqueline, Wu, Kehua, Janisch, Linda, Karrison, Theodore, House, Larry K., Innocenti, Federico, Cohen, Ezra E. W., Ratain, Mark J.

“…Purpose Irinotecan and thalidomide are commonly administered antineoplastic drugs. Combination treatment may potentiate their antitumor effect and protect…”
Get full text

Personalized targeted therapy for lung cancer by Wu, Kehua, House, Larry, Liu, Wanqing, Cho, William C S

“…由于每一肺癌患者在临床特征、预后、治疗反应和耐受性方面的进展都是独特的，所以肺癌被认为是异质性疾病。个体化用药是指运用标志物来预测哪些患者更易获益于某种治疗。对于肺癌而言，日趋完善的表皮生长因子受体（epidermal growth factor receptor,…”
Get full text

肺癌的下一代测序技术 by 南娟(翻译), 曹志成(校对), Larry House, William Chi Cho

“…肺癌在生物学上具有侵袭性，并且是癌症相关死亡的主要原因。根据临床特征、预后、对治疗的反应和耐受性，每一例肺癌患者的进展均是独特的。传统上基于毛细管的单基因测序的第一代技术（如Sanger测序法）已被允许大量平行测序且成本更低、通量更高的下一代测序技术（next-generation sequencing,…”
Get full text

Next-generation sequencing for lung cancer by Wu, Kehua, Huang, R Stephanie, House, Larry, Cho, William Chi

“…肺癌在生物学上具有侵袭性，并且是癌症相关死亡的主要原因。根据临床特征、预后、对治疗的反应和耐受性，每一例肺癌患者的进展均是独特的。传统上基于毛细管的单基因测序的第一代技术（如Sanger测序法）已被允许大量平行测序且成本更低、通量更高的下一代测序技术（next-generation sequencing,…”
Get full text

Clinically Actionable Genotypes for Anti-Cancer Prescribing Among >1500 Patients with Pharmacogenomic Testing by Reizine, Natalie M., Danahey, Keith, Truong, Tien M., George, David, House, Larry K., Karrison, Theodore G., van Wijk, Xander M.R., Yeo, Kiang-Teck J., Ratain, Mark J., O’Donnell, Peter H.

“…Nearly one-third of individuals have actionable germline genetic variants that may impact the choice or dosing of common anti-cancer therapies. Preemptive…”
Get full text

Pilot Findings of Pharmacogenomics in Perioperative Care: Initial Results From the First Phase of the ImPreSS Trial by Truong, Tien M., Apfelbaum, Jeffrey L., Danahey, Keith, Schierer, Emily, Ludwig, Jenna, George, David, House, Larry, Karrison, Theodore, Shahul, Sajid, Anitescu, Magdalena, Choksi, Anish, Hartman, Seth, Knoebel, Randall W., van Wijk, Xander M. R., Yeo, Kiang-Teck J., Meltzer, David O., Ratain, Mark J., O’Donnell, Peter H.

Get full text

Pilot Findings of Pharmacogenomics in Perioperative Care: Initial Results From the First Phase of the ImPreSS Trial by Truong, Tien M., Apfelbaum, Jeffrey L., Danahey, Keith, Schierer, Emily, Ludwig, Jenna, George, David, House, Larry, Karrison, Theodore, Shahul, Sajid, Anitescu, Magdalena, Choksi, Anish, Hartman, Seth, Knoebel, Randall W., van Wijk, Xander M. R., Yeo, Kiang-Teck J., Meltzer, David O., Ratain, Mark J., O’Donnell, Peter H.

“…Pharmacogenomics, which offers a potential means by which to inform prescribing and avoid adverse drug reactions, has gained increasing consideration in other…”
Get full text

A drug-drug interaction study of capecitabine and celecoxib in patients with advanced solid malignancies by Ramirez, Jacqueline, House, Larry, Karrison, Theodore G., Janisch, Linda A., Turcich, Michelle, Salgia, Ravi, Ratain, Mark J., Sharma, Manish

“…Abstract only e14066 Background: Warfarin is an anticoagulant and CYP2C9 substrate commonly used in oncology patients. Several studies suggest a drug-drug…”
Get full text

Next-generation sequencing for lung cancer by Wu, Kehua, Huang, R Stephanie, House, Larry, Cho, William Chi

“…Lung cancer is biologically aggressive and is the leading cause of cancer-related deaths. The development of lung cancer is unique in each patient according to…”
Get more information

In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7 by House, Larry, Ramirez, Jacqueline, Seminerio, Michael, Mirkov, Snezana, Ratain, Mark J.

“…1. Aprepitant, an oral antiemetic, commonly used in the prevention of chemotherapy-induced nausea and vomiting, is primarily metabolized by CYP3A4. Aprepitant…”
Get full text

Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients by COHEN, Ezra E. W, KEHUA WU, HOUSE, Larry, RAMIREZ, Jacqueline, UNDEVIA, Samir D, FLEMING, Gini F, GAJEWSKI, Thomas F, RATAIN, Mark J, HARTFORD, Christine, KOCHERGINSKY, Masha, NAPOLI EATON, Kimberly, YUANYUAN ZHA, NALLARI, Anitha, MAITLAND, Michael L, FOX-KAY, Kammi, MOSHIER, Kristin

“…Sirolimus is the eponymous inhibitor of the mTOR; however, only its analogs have been approved as cancer therapies. Nevertheless, sirolimus is readily…”
Get full text

Evaluation of utility of pharmacokinetic studies in phase I combination trials by Wu, Kehua, House, Larry, Ramirez, Jacqueline, Ratain, Mark J.

“…Abstract only 2611 Background: There are many phase I clinical combination trials including drug-drug interaction (DDI) studies, but very few of them report…”
Get full text